EBX-102-02 is a next-generation full-spectrum microbiome product that contains a high-diversity microbiome consortium, stabilised within a dried, off-white odourless powder. EBX-102-02 is designed to ...

The Tecan Group (SIX Swiss Exchange: TECN) today published the agenda of the Annual General Meeting on April 10, 2025. Karen Huebscher, who has served as a member of the Board of Directors since 2012, ...

Signature d’un avenant n°4 au contrat de financement obligataire en vigueur afin de poursuivre le retournement stratégique de Safe ...

The new non-executive employee received an option to purchase 35,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to $2.60, which was the ...

OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its partnership with the ...

“This new loan financing strengthens our financial position, providing additional support for developing Mother Bracelet,” said Koji Eguchi, Chief Executive Officer of MEDIROM.

Hyperfine, Inc. sold nine commercial Swoop® systems in the fourth quarter of 2024, compared to seven in the fourth quarter of 2023. Gross margin for the fourth quarter of 2024 was $0.8 million, ...

Under the terms of the new Contract Manufacturing Agreement, effective as of March 17, 2025, AVITA Medical is to manufacture PermeaDerm at its state-of-the-art manufacturing facility in Ventura, ...

Brian Stephenson, Ph.D. will depart from the Company for personal reasons. Dr. Stephenson's departure was not the result of a disagreement with the Company on any matters relating to the Company’s ...

FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, ...

F573 is a caspase inhibitor and a potential Category 1 new drug for the treatment of acute/acute on-chronic liver failure (“ALF/ACLF”). Completion of the Phase 2 clinical trial of F573 as a treatment ...

EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its ...